Meeting
2020 ASCO Virtual Scientific Program
Efficacy and safety of direct oral anticoagulants (DOACs) and low molecular weight heparin (LMWH) for primary prevention of venous thromboembolism (VTE) in ambulatory cancer patients.
Authors
Mina Shenouda
Tampa General Hospital, Tampa, FL
Mina Shenouda , Ruchi Desai , Michael Vishal Jaglal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Palliative Care and Symptom Management
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12088)
DOI
10.1200/JCO.2020.38.15_suppl.12088
Abstract #
12088
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
An analysis of the safety and efficacy of rivaroxaban (Riv) and low molecular weight heparin (LMWH) in gastrointestinal cancer-associated venous thromboembolism (GICA-VTE).
First Author: Alejandro Recio Boiles
Poster
2022 ASCO Annual Meeting
Risk of intracranial hemorrhage with direct oral anticoagulants versus low molecular weight heparin in glioblastoma: A retrospective cohort study.
First Author: Lauren Reed-Guy
Poster
2022 ASCO Annual Meeting
Real-world utilization and comparative effectiveness of treatment options in cancer-associated thrombosis: A propensity score weighed analysis.
First Author: Irbaz Bin Riaz
Poster
2021 ASCO Annual Meeting
The comparative effectiveness of direct oral anti-coagulants and low molecular weight heparins for prevention of recurrent venous thromboembolism in cancer: The CANVAS pragmatic randomized trial.
First Author: Deborah Schrag